Premium
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
Author(s) -
Peyvandi Flora,
Miri Syna,
Bucciarelli Paolo,
Valsecchi Carla,
Schiavone Lucia,
Boscarino Marco,
Palla Roberta,
Mannucci Pier Mannuccio,
Rosendaal Frits Richard
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17249
Subject(s) - persistence (discontinuity) , subclass , concomitant , haemophilia a , medicine , haemophilia , immunology , gastroenterology , antibody , pediatrics , geotechnical engineering , engineering
Summary We investigated longitudinally the behaviour of anti‐factor VIII (anti‐FVIII) IgG subclasses for 6 months from inhibitor development in 43 patients from the Survey of Inhibitors in Plasma‐Products Exposed Toddlers (SIPPET) trial who developed persistent or transient inhibitors. We first analysed 43 patients within 60 days post inhibitor detection. Then, 14 of these 43 patients were studied at five time points over 6 months. Our study showed that during the first 60 days, the risk of inhibitor persistence increased with the concomitant presence of an increasing number of IgG subclasses. Over the 6‐month period post inhibitor detection, only the IgG2 subclass could be considered a hallmark of inhibitor persistence.